Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080808 · ClinicalTrials.gov registry record · Phase 2
Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00080808: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00080808 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 111 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00080808, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
RATIONALE: Nerve-sparing radical prostatectomy with nerve grafting followed by standard therapies for erectile dysfunction may be effective in helping patients with prostate cancer improve sexual satisfaction and quality of life. It is not yet known whether erectile dysfunction therapy and nerve-sparing prostatectomy are more effective with or without nerve grafting. PURPOSE: This randomized phase II trial is studying nerve grafting and standard therapy to see how well they work compared to standard therapy alone in treating erectile dysfunction in patients undergoing nerve-sparing radical prostatectomy for localized prostate cancer.
Interventions
- DRUG Papaverine
- PROCEDURE conventional surgery
- DRUG Sildenafil citrate
- DRUG Alprostadil (E1)
- DRUG Phentolamine mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2001-08 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080808
The ClinicalTrials.gov registry entry for NCT00080808 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Papaverine is the first listed.
NCT00080808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080808 about?
NCT00080808 is a clinical study titled "Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer". RATIONALE: Nerve-sparing radical prostatectomy with nerve grafting followed by standard therapies for erectile dysfunction may be effective in helping patients with prostate cancer improve sexual satisfaction and quality of life. It is not yet known whether erectile dysfunction therapy and nerve-spa...
What is the current status of trial NCT00080808?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2001-08. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00080808?
The interventions under investigation include: Papaverine (DRUG), conventional surgery (PROCEDURE), Sildenafil citrate (DRUG), Alprostadil (E1) (DRUG), Phentolamine mesylate (DRUG).
Who is sponsoring clinical trial NCT00080808?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.